Psoriatic Arthritis
Yuflyma becomes fourth Humira biosimilar to receive interchangeability status
The FDA has accepted Yuflyma as an interchangeable biosimilar to adalimumab for the treatment of multiple chronic inflammatory diseases, Celltrion USA announced in a press release.
Tremfya reduces psoriatic arthritis severity, progression of structural damage
Editor’s note: This is a developing news story. Please check back soon for updates.
‘It is encouraging’: Sotyktu sails through phase 3 trial in psoriatic arthritis
Sotyktu significantly outperformed placebo for the treatment of psoriatic arthritis in a phase 3 trial, meeting key endpoints at 16 weeks, according to late-breaking data presented at the American Academy of Dermatology annual meeting.
IL-23 inhibitors may reduce psoriatic arthritis risk among patients with psoriasis
ORLANDO — Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, according to a speaker at the American Academy of Dermatology Annual Meeting.
Deucravacitinib improves cutaneous lupus erythematosus activity
ORLANDO — Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according to a presenter at the American Academy of Dermatology Annual Meeting.
First four Stelara biosimilars launch in US; ‘white labeling’ threatens market ‘vibrancy’
Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference product manufacturer, Janssen Pharmaceuticals, which set timelines for their market entries.
Upadacitinib, deucravacitinib ‘the top two’ small molecules for psoriatic arthritis
Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic arthritis, according to data published in Therapeutic Advances in Musculoskeletal Disease.
VIDEO: JAK inhibitors in dermatology effective, ‘safer than we could have ever hoped for’
MIAMI BEACH, Fla. — Janus kinase inhibitors are an incredibly important, new tool that have exemplified both high efficacy and safety, according to a speaker at South Beach Symposium.
Physicians may overlook ‘deep sense of vulnerability’ in patients with psoriatic arthritis
Uncertainty about future care and life impacts were among the top concerns for patients with psoriatic arthritis, but not for physicians, who highly prioritized individual symptoms, according to data published in ACR Open Rheumatology.
‘We applaud CMS’: Two more rheumatology drugs bound for Medicare price negotiation
The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — a move applauded by experts as they await the impact of the first-round of discounts anticipated next year.